Moderna, Pfizer and COVID-19

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...
The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...
Moderna's COVID sales have been declining, and the company has been trimming costs. But it doesn't have a huge growth ...
Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...
Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and ...